|
1
|
Kane RC, Bross PF, Farrell AT and Pazdur
R: Velcade: U.S. FDA approval for the treatment of multiple myeloma
progressing on prior therapy. Oncologist. 8:508–513. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Brodmann S, GyrKlaas E, Cathomas R,
Girardi V and von Moos R: Severe hyponatremia in a patient with
mantle cell lymphoma treated with bortezomib. A case report and
review of the literature. Onkologie. 30:651–654. 2007.PubMed/NCBI
|
|
3
|
Richardson PG, Sonneveld P, Schuster MW,
Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D,
Lonial S, Goldschmidt H, et al: Bortezomib or high-dose
dexamethasone for relapsed multiple myeloma. N Engl J Med.
352:2487–2498. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Belch A, Kouroukis CT, Crump M, Sehn L,
Gascoyne RD, Klasa R, Powers J, Wright J and Eisenhauer EA: A phase
II study of bortezomib in mantle cell lymphoma: The National cancer
institute of Canada clinical trials group trial IND.150. Ann Oncol.
18:116–121. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
O'Connor OA, Wright J, Moskowitz C, Muzzy
J, MacGregor-Cortelli B, Stubblefield M, Straus D, Portlock C,
Hamlin P, Choi E, et al: Phase II clinical experience with the
novel proteasome inhibitor bortezomib in patients with indolent
non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol.
23:676–684. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Orlowski RZ, Stinchcombe TE, Mitchell BS,
Shea TC, Baldwin AS, Stahl S, Adams J, Esseltine DL, Elliott PJ,
Pien CS, et al: Phase I trial of the proteasome inhibitor PS-341 in
patients with refractory hematologic malignancies. J ClinOncol.
20:4420–4427. 2002. View Article : Google Scholar
|
|
7
|
Van Waes C, Chang AA, Lebowitz PF, Druzgal
CH, Chen Z, Elsayed YA, Sunwoo JB, Rudy SF, Morris JC, Mitchell JB,
et al: Inhibition of nuclear factor-kappaB and target genes during
combined therapy with proteasome inhibitor bortezomib and
reirradiation in patients with recurrent head-and-neck squamous
cell carcinoma. Int J Radiat Oncol Biol Phys. 63:1400–1412. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jagannath S, Barlogie B, Berenson J,
Siegel D, Irwin D, Richardson PG, Niesvizky R, Alexanian R,
Limentani SA, Alsina M, et al: A phase 2 study of two doses of
bortezomib in relapsed or refractory myeloma. Br J Haematol.
127:165–172. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Schwartz WB, Bennett W, Curelop S and
Bartter FC: Syndrome of renal sodium loss and hyponatremia probably
resulting from inappropriate secretion of antidiuretic hormone. Am
J Med. 23:529–542. 1957. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ellison DH and Berl T: The syndrome of
inappropriate antidiuresis. N Engl J Med. 356:2064–2072. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Waikar SS, Mount DB and Curhan GC:
Mortality after hospitalization with mild, moderate, and severe
hyponatremia. Am J Med. 122:857–865. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wald R, Jaber BL, Price LL, Upadhyay A and
Madias NE: Impact of hospital-associated hyponatremia on selected
outcomes. Arch Intern Med. 170:294–302. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Verbalis JG, Barsony J, Sugimura Y, Tian
Y, Adams DJ, Carter EA and Resnick HE: Hyponatremia-induced
osteoporosis. J Bone Miner Res. 25:554–563. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kinsella S, Moran S, Sullivan MO, Molloy
MG and Eustace JA: Hyponatremia independent of osteoporosis is
associated with fracture occurrence. Clin J Am Soc Nephrol.
5:275–280. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gillessen S, Groettup M and Cerny T: The
proteasome, a new target for cancer therapy. Onkologie. 25:534–539.
2002.PubMed/NCBI
|
|
16
|
Ludwig H, Khayat D, Giaccone G and Facon
T: Proteasome inhibition and its clinical prospects in the
treatment of hematologic and solid malignancies. Cancer.
104:1794–1807. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Richardson PG, Weller E, Jagannath S,
Avigon DE, Alsina M, Schlossman RL, Mazumder A, Munshi NC, Ghobrial
IM, Doss D, et al: Multicenter, phase I, dose-escalation trial of
lenalidomide plus bortezomib for relapsed and relapsed/refractory
multiple myeloma. J Clin Oncol. 27:5713–5719. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Davies AM, Ruel C, Lara PN, Lau DH,
Gumerlock PH, Bold R, Shibata S, Lenz HJ, Schenkein DP and Gandara
DR: The proteasome inhibitor bortezomib in combination with
gemcitabine and carboplatin in advanced non-small cell lung cancer:
A California cancer consortium phase I study. J Thorac Oncol.
3:68–74. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Reynolds RM and Seckl JR: Hyponatraemia
for the clinical endocrinologists. Clin Endocrinol (Oxf).
63:366–374. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sherlock M and Thompson CJ: The syndrome
of inappropriate antidiuretic hormone: Current and future
management options. Eur J Endocrinol. 162 Suppl 1:S13–S18. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Robertson GL: Posterior pituitary. Felig
P, Baxter JD, Broadus AE and Frohman LA: Endocrinology and
Metabolism. (1st edition). (New York). McGraw-Hill. 338–385.
1986.
|
|
22
|
Palmer BF: Hyponatremia in patients with
central nervous system disease: SIADH versus CSW. Trends Endocrinol
Metab. 14:182–187. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Martin PY, Abraham WT, Lieming X, Olson
BR, Oren RM, Ohara M and Schrier RW: Selective V2-receptor
vasopressin antagonism decreases urinary aquaporin-2 excretion in
patients with chronic heart failure. J Am Soc Nephrol.
10:2165–2170. 1999.PubMed/NCBI
|
